In the context of the development of a novel self-injection device for the treatment of ITP, a global biopharmaceutical company is seeking patients diagnosed with Immune Thrombocytopenic Purpura (ITP) to be recruited for a simulated use (usability) study.
The usability study will consist of simulated use of prototypes of the self-injection device onto an injection pad. The prototypes used for the study will not contain any needles nor medication. The objective of the study is to verify that the intended users can safely and effectively use the self-injection device, and to gather feedback on the device user interface.
Testing will take place in London between the end of September and the beginning of October 2021.
Sessions will last up to 90 minutes and compensation will be offered in appreciation for time spent and the feedback provided during the study.
If interested in taking part, you can contact Hayley Algar
Tel: +44 (0) 1473 836302 ext 102